Quick Answer
Candel Therapeutics, Inc. reported Total Assets of $125.19 million for fiscal year 2025.
Candel Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $125.19M | +17.2% |
| 2024 | $106.87M | +159.4% |
| 2023 | $41.20M | -47.0% |
| 2022 | $77.69M | -12.9% |
| 2021 | $89.20M | +133.0% |
| 2020 | $38.28M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $93.60M | +335.0% | -11.7% |
| June 30, 2025 | $105.97M | +300.1% | +10.5% |
| March 31, 2025 | $95.91M | +207.2% | -10.3% |
| December 31, 2024 | $106.87M | +159.4% | +396.7% |
| September 30, 2024 | $21.52M | -57.0% | -18.8% |
| June 30, 2024 | $26.48M | -54.9% | -15.2% |
| March 31, 2024 | $31.22M | -53.6% | -24.2% |
| December 31, 2023 | $41.20M | -47.0% | -17.7% |
- Candel Therapeutics, Inc. showed an increase of +17.2% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Candel Therapeutics, Inc.’s total assets has grown by 227.0% (from $38.28 million to $125.19 million).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: